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MaA unifying deﬁnition of what constitutes high-risk percutaneous coronary intervention remains elusive. This
reﬂects the existence of several recognized patient, anatomic, and procedural characteristics that, when combined,
can contribute to elevating risk. The relative inability to withstand the adverse hemodynamic sequelae of
dysrhythmia, transient episodes of ischemia-reperfusion injury, or distal embolization of atherogenic material asso-
ciated with coronary intervention serve as a common thread to tie this patient cohort together. This enhanced
susceptibility to catastrophic hemodynamic collapse has triggered the development of percutaneous cardiac assist
devices such as the intra-aortic balloon pump, Impella (Abiomed Inc., Danvers, Massachusetts), TandemHeart
(CardiacAssist, Inc., Pittsburgh, Pennsylvania), and extracorporeal membranous oxygenation to provide adjunctive
mechanical circulatory support. In this state-of-the-art review, we discuss the physiology underpinning their
application. Thereafter, we examine the results of several randomized multicenter trials investigating their use in
high-risk coronary intervention to determine which patients would beneﬁt most from their implantation and whether
there is a signal to delineate whether they should be used in an elective pre-procedure, standby, rescue, or routine
post-procedure fashion. (J Am Coll Cardiol Intv 2015;8:229–44) © 2015 by the American College of Cardiology
Foundation.T he evolution of percutaneous coronaryintervention (PCI) has witnessed unprece-dented advances in the past 2 decades. In
the wake of such progress, interventional cardiolo-
gists are now attempting revascularization of more
complex coronary anatomy in patients often
declined for surgical intervention. Yet with greater
complexity comes greater risk, hence the develop-
ment of percutaneous mechanical circulatory support
(MCS) devices. Borne from a sound physiological plat-
form, in theory they serve to maintain coronary perfu-
sion pressure and reduce myocardial workload,
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the criteria that elevate PCI to the high-risk category.
Thereafter, we compare and contrast the physiology
and evidence base underpinning MCS use to deter-
mine where these devices sit in the wider context of
high-risk PCI.
WHAT DEFINES HIGH-RISK PCI?
A universally accepted deﬁnition of high-risk PCI
remains elusive. This reﬂects the myriad adverse
clinical, anatomic, and hemodynamic factors that, if
taken in isolation, are potentially surmountable butip with King’s College London and King’s College
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AB BR E V I A T I O N S
AND ACRONYM S
AMI = acute myocardial
infarction
CBF = coronary blood ﬂow
CI = cardiac index
CO = cardiac output
CS = cardiogenic shock
ECMO = extracorporeal
membrane oxygenation
IABP = intra-aortic balloon
pump
LV = left ventricular
MAP = mean arterial pressure
MCS = mechanical circulatory
support
PCAD = percutaneous
circulatory assist device
PCI = percutaneous coronary
intervention
PPCI = primary percutaneous
coronary intervention
RCT = randomized controlled
trial
STEMI = ST-segment elevation
ardial infarction
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231when combined, will signiﬁcantly increase the chance
of periprocedural, subacute, medium- and long-term
major adverse cardiac and cerebrovascular events
occurring.
HIGH-RISK CRITERIA USED IN
THE CURRENT EVIDENCE BASE
The diversity of criteria adopted by investigators to
study the performance of percutaneous circulatory
assist devices (PCADs) (Table 1, Online Appendix)
would suggest a lack of consensus on what deﬁnes
high-risk PCI. This makes robust intertrial compari-
son speculative at best and standardization prob-
lematic, especially when patient characteristics,
procedural adjuncts, timing of hemodynamic sup-
port, and metrics of risk are largely heterogeneous
(1,2). To this end, the deﬁnition of high-risk
PCI becomes somewhat arbitrary, reﬂecting a need
to pigeonhole the population under investigation
to satisfy inclusion criteria rather than corresponding
to universally accepted parameters. This also limits
our ability to recommend one model of risk stratiﬁ-
cation over another. Moreover, risk scores may
identify who might beneﬁt from MCS, but they
do not, as yet, inform the operator as to which PCAD
to use or whether it should be used in an elective
pre-procedure, standby, rescue, or routine post-
procedure fashion. Despite these inconsistencies,
there is a common thread. It is the relative inability of
the high-risk patient to withstand the deleterious
hemodynamic consequences of dysrhythmia, tran-
sient intervals of ischemia-reperfusion injury, or the
distal embolization of atherogenic material (i.e., the
no-reﬂow phenomenon) associated with PCI. A high-
risk patient may have signiﬁcantly attenuated car-
diovascular reserve and be increasingly susceptible
to post-ischemic stunning. The onus falls on the
heart team to recognize this patient subset, antici-
pate potential difﬁculties that may occur during the
procedure, and decide whether MCS is an appro-
priate intervention. Otherwise, a chain of deleterious
events may ensue, leading to further reduction in
cardiac output (CO) and an ampliﬁcation of ischemia,
culminating in cardiogenic shock (CS) or malignant
ventricular arrhythmia. Conversely, the patient may
already be in CS on presentation, a diagnosis based
on evidence of hypotension (systolic blood
pressure <90 mm Hg), end-organ hypoperfusion
(cool extremities and urine output <30 ml/h), a car-
diac index (CI) of #2.2 l/min/m2, and a pulmonary
capillary wedge pressure of $15 mm Hg (3). A mixed
venous blood oxygen saturation <65% may also be
incorporated (4).KEY FUNDAMENTALS OF MECHANICAL
CIRCULATORY SUPPORT
Once Kantrowitz et al. (5) had performed the
ﬁrst-in-human intra-aortic balloon pump
(IABP) implantation in 1968, the following 4
basic characteristics for an MCS device to
have a therapeutic impact on CS management
had already been proposed: effective inser-
tion with minimal surgical application;
simplicity of initiation and maintenance for
widespread use by minimally trained profes-
sional personnel; capability for aiding the
coronary and peripheral circulation inter-
mittently or continuously for hours or days;
signiﬁcant support for the ischemic myocar-
dium by reducing its work (Figures 1 and 2).
MAINTENANCE OF
END-ORGAN PERFUSION
The landmark SHOCK (Should We Emergently
Revascularize Occluded Coronaries for Car-
diogenic Shock) trial demonstrated a mid-
to long-term survival advantage for early
revascularization versus medical stabilization
for managing acute myocardial infarction (AMI)
complicated by CS (3,6,7). Although not primarily a
trial of IABP, $86% of participants in each trial arm
received a balloon pump, reﬂecting both the severity
of the clinical setting and it being the recognized
mainstay of adjunctive MCS at the time. Moreover,
IABP was recommended in the study design for those
patients randomized to medical stabilization. Post-
hoc analysis of the parallel SHOCK trial registry also
conﬁrmed the beneﬁt of IABP for lowering in-hospital
mortality (8,9). The SHOCK investigators introduced
the concept of cardiac power output (in W ¼ mean
arterial pressure [MAP]  CO/451) and cardiac power
index (in W/m2 ¼ cardiac power output/body
surface area) as novel hemodynamic parameters for
the assessment and subsequent management of CS.
Although seldom performed now, cardiac power
output (p ¼ 0.002) and cardiac power index (p ¼
0.004) were shown to be the strongest independent
predictors of in-hospital mortality (10). A core func-
tion, therefore, of any PCAD should be to augment
MAP and CO to maintain end-organ perfusion,
thereby avoiding (or rationalizing) the use of sup-
plementary vasopressor or inotrope therapy.
OPTIMIZATION OF MYOCARDIAL PERFUSION
When the epicardial coronary arteries are patent,
myocardial tissue perfusion is almost universally
myoc
TABLE 1 Clinical, Anatomic, and Hemodynamic Criteria Used
to Identify the High-Risk Percutaneous Coronary Intervention
Patient
Clinical criteria
Cardiogenic shock occurring within 24 h or at the start of coronary
intervention
Left ventricular systolic dysfunction on presentation: ejection
fraction #30%–40%
Killip class II–IV on presentation or congestive heart failure
Coronary intervention after resuscitated cardiac arrest within 24 h
ST-segment elevation myocardial infarction
Acute coronary syndrome complicated by unstable hemodynamics,
dysrhythmia, or refractory angina
Mechanical complications of acute myocardial infarction
Age $70–80 yrs
History of cerebrovascular disease, diabetes, renal dysfunction, or
chronic lung disease
Anatomic criteria
Intervention to an unprotected left main coronary artery or left main
equivalent
Multivessel disease
Distal left main bifurcation intervention
Previous coronary artery bypass graft surgery including intervention
to a graft, particularly a degenerated graft
Last remaining coronary conduit
Duke Myocardial Jeopardy score $8/12
Target vessel providing a collateral supply to an occluded second
vessel that supplies >40% of the left ventricular myocardium
SYNTAX score $33
Hemodynamic criteria
Cardiac index <2.2 l/min/m2
Pulmonary capillary wedge pressure >15 mm Hg
Mean pulmonary artery pressure >50 mm Hg
A summary of the most frequently used metrics to deﬁne high risk in studies of
mechanical circulatory support for percutaneous coronary intervention. This table
is by no means exhaustive or validated but provides a snapshot of the wide range
of clinical, anatomic, and hemodynamic criteria that various investigators have
used as inclusion criteria in observational and randomized studies. See the Online
Appendix for a more complete list of high-risk criteria.
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232determined by an inverse correlation with microvas-
cular resistance and the pressure gradient between
the driving aortic force (proximal to the subtended
myocardium) and coronary sinus/right atrial pressure
(the distal vascular bed). During AMI, the microvas-
cular resistance is high as a result of vasoconstriction,
plugging related to microemboli, and ischemia-
reperfusion injury. In CS, this is compounded by a
decrease in driving pressure and an increase in right
atrial pressure (11). Mechanical support devices
should ideally facilitate myocardial perfusion by
increasing the MAP and reducing right atrial pressure
to overcome the higher resistance encountered in the
infarct-related territory.
During systole, ventricular contraction exerts a
compressive force on the microvasculature, and dur-
ing ventricular relaxation in diastole, a large suction
effect. As such, coronary blood ﬂow (CBF) occurs pre-
dominantly in diastole (12). The ideal PCAD shouldlower left ventricular (LV) end-diastolic pressure.
This, in turn, diminishes microvascular resistance
and increases the perfusion pressure, subsequently
increasing CBF and hencemyocardial oxygen delivery.
INTRA-AORTIC BALLOON
COUNTERPULSATION
The beneﬁt of the IABP is underpinned by the concept
of diastolic augmentation (13,14). Theoretically, this
gives rise to greater myocardial perfusion by
increasing the coronary pressure gradient from the
aorta to the epicardial coronary circulation at a time
when the aortic valve is closed (15). Active deﬂation
immediately before the onset of systole and precisely
at the beginning of isovolumic contraction creates a
dead space in the thoracic aorta, which reduces
afterload and promotes forward ﬂow from the LV.
This stimulates a reduction in LV end-diastolic pres-
sure, volume, wall tension, and work (leading to a
lowering of myocardial oxygen demand) along with
preservation of or an increase in stroke volume,
ejection fraction and overall CO (15). The magnitude
of the hemodynamic effect is dependent on the
balloon size in proportion to the aorta. The larger the
balloon is, the greater the volume of blood displaced
(Figure 1) (15). The blood volume displaced toward the
aortic root has been calculated at 6.4% (during 1:1
inﬂation) and 10.0% (with 1:2 support) of the nominal
balloon volume (16). The remainder is stored in the
compliant aortic wall during balloon inﬂation or
distributed among the branches along the arch.
Although this percentage appears small, it represents
a signiﬁcant fraction of baseline coronary ﬂow (16).
An increase in aortic compliance (or reduction in
systemic vascular resistance), however, will result in
diminution of the IABP effect. Moreover, as heart rate
increases to maintain CO, LV and aortic diastolic
ﬁlling times decrease, resulting in less balloon
augmentation per unit of time elapsed. There is
conﬂicting evidence on the degree of post-stenotic
CBF augmentation achieved despite the increase in
perfusion pressure. Some reports demonstrate no
increase in CBF distal to a critical stenosis (17–19),
whereas others have revealed an enhancement of
distal ﬂow, regardless of the presence or absence of
obstruction (20,21). As such, the predominant beneﬁt
of IABP on high-risk patients with severe coronary
stenosis may relate to a reduction in oxygen demand
through LV systolic unloading over and above that
stimulated by diastolic augmentation of CBF (19).
OBSERVATIONAL AND REGISTRY DATA. A recent U.S.
CathPCI Registry analysis revealed that IABP use was
FIGURE 1 Percutaneous Coronary Assist Devices
A comparison of the intra-aortic balloon pump versus the Impella (Abiomed Inc., Danvers, Massachusetts) versus the TandemHeart (CardiacAssist, Inc., Pittsburgh,
Pennsylvania) devices. (Permission to reproduce images received from Maquet Cardiopulmonary AG, Rastatt, Germany; CardiacAssist, Inc., Pittsburgh, Pennsylvania; and
BMJ Publishing Group Ltd., London, United Kingdom.)
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233limited to just 10.5% of all high-risk PCI procedures
(22). This could partly reﬂect a lack of interoperator
and interhospital consensus on what is deemed high
risk. Indeed, the criteria used to deﬁne high-risk were
superimposed retrospectively by the authors of the
analysis and were not labeled as such by the opera-
tors at individual hospitals inputting the raw data
(22). This should negate any selection bias at the
source but could amplify any disconnect between
what the operator or speciﬁc hospital protocol would
recognize as high risk and what the registry analysis
deems to be high risk. Furthermore, the registry
analysis did not provide any information on the
timing of MCS. Notably, after multivariate adjust-
ment, neither in-hospital mortality nor complication
rate varied between hospitals categorized by their
frequency of IABP implantation. We must also accepthow difﬁcult it is to quantify the expertise, familiar-
ity, and conﬁdence that an individual operator has
with the “kit” and what effect this, and the overriding
protocol of the center, has on their decision to use a
mechanical adjunct.
Similarly, a EuroHeart Survey PCI Registry of those
patients revascularized for CS as a complication of
AMI revealed that the IABP was only used in 24.8% of
cases (23). Interhospital differences in the deﬁnition
of CS may have led to signiﬁcant selection bias. Again
IABP use did not confer an overall survival advantage
in this patient cohort (n ¼ 653), lending credence to
the decision not to use the device routinely (23).
Ultimately, current data from registries and retro-
spective analyses cannot be used to conﬁdently
support the IABP in high-risk PCI despite its being
a low-risk therapeutic option. Some studies have
FIGURE 2 Percutaneous Extracorporeal Membrane Oxygenation
Venoarterial extracorporeal membrane oxygenation provides continuous, nonpulsatile cardiac output. Devices have become more portable so
they can now be implanted percutaneously. Permission to reproduce image received from Maquet Cardiopulmonary AG, Rastatt, Germany.
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234shown a signiﬁcant beneﬁt of IABP in terms of in-
hospital mortality (24) and freedom from catheteri-
zation laboratory events (25,26), whereas others have
demonstrated no beneﬁt (22,27–30) or even a trend
toward harm (23,31).
RANDOMIZED TRIAL DATA. Early ST-segment ele-
vation myocardial infarction (STEMI) trials have
shown beneﬁt when IABP was implanted post-
procedure for 36 to 48 h (4,32,33). Extrapolation to
modern-day PCI, however, is difﬁcult because pa-
tients were treated primarily by balloon angioplasty.
The IABP has also been associated with reduced
mortality when combined with thrombolysis for
AMI (8,31). Latter-day single-center, randomized
controlled trials (RCTs) have been underpowered to
provide meaningful answers; trial participants and
metrics of risk are heterogeneous, timing of MCS
initiation varies, and their ﬁndings conﬂict (Online
Appendix).
THE BCIS-1 TRIAL. The BCIS-1 (Balloon Pump-
Assisted Coronary Intervention Study-1) was the
ﬁrst prospective, open, multicenter RCT designed to
determine whether elective IABP insertion before
high-risk single-vessel or multivessel PCI was able toreduce major adverse cardiac and cerebrovascular
events at 28 days (34). Metrics of high risk included a
modiﬁcation of the Duke Jeopardy score. There was,
however, no protocol-mandated assessment of coro-
nary disease complexity or requirement for complete
revascularization of all amenable lesions. Bailout
IABP was permitted in the no-planned IABP group if
clinical circumstances justiﬁed the intervention.
There were similar rates of the primary endpoint of
major adverse cardiac and cerebrovascular events in
both treatment arms (15.2% elective IABP vs. 16.0%
no planned IABP, p ¼ 0.85). There was no signiﬁcant
difference in the secondary endpoint of 6-month
mortality or overall rates of bleeding. When broken
down, there were signiﬁcantly more minor bleeds in
the elective IABP arm (15.9% elective IABP vs. 7.3%
no-planned IABP arm, p ¼ 0.02). Conversely, peri-
procedural complications occurred more frequently
in the no-planned IABP arm, predominantly due to
procedural hypotension (1.3% vs. 10.7% in favor of
elective IABP, p < 0.001), which might explain the
need for rescue/bailout IABP in 18 patients (12%).
Overall, the study did not support the use of pro-
phylactic IABP insertion before high-risk PCI. Given
the rate of crossover, an initial strategy of standby
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235IABP for PCI in those patients with compromised
myocardial reserve and extensive coronary artery
disease could attenuate the delay in gaining arterial
access, and would therefore seem a sensible strategy.
Interestingly, those patients requiring rescue IABP
in the no-planned IABP group had a signiﬁcantly
higher BCIS-1 Jeopardy score (Jeopardy score 11.2 vs.
10.2, p ¼ 0.02), further emphasizing the need for
standby MCS in those at the extreme end of the risk
spectrum.
Five-year all-cause mortality data from the BCIS-1
study are now available with complete capture of all
trial participants using a central national database
(35). The Kaplan-Meier curves demonstrated a sig-
niﬁcant survival advantage in favor of elective IABP
(hazard ratio: 0.66, 95% conﬁdence interval: 0.44 to
0.98, p ¼ 0.039), which appear to be diverging further
still at the 5-year mark. Analysis by treatment
received also conﬁrmed a mortality beneﬁt in those 18TABLE 2 Current Guideline Recommendations for the Use of Percuta
Guidelines, Year (Ref.#) IABP
American College of Cardiology/American Heart Associat
PCI, 2011 (48) A hemodynamic support device is recommen
with pharmacological therapy.
Class I, Level of Evidence: B
Elective insertion of an appropriate hemodyn
Class IIb, Level of Evidence: C
High-risk patients include:
 Unprotected left main or last remaining con
 Cardiogenic shock.
STEMI, 2013 (44) IABP can be useful for patients in cardiogenic
who do not quickly stabilize with pharma
Class IIa, Level of Evidence: B
UA/NSTEMI, 2013 (50) IABP is reasonable in UA/NSTEMI patients fo
frequently recurring severe ischemia desp
medical therapy, hemodynamic instability
angiography, and for mechanical complica
Class IIa, Level of Evidence: C
European Soc
PCI, 2014 (49) Short-term mechanical circulatory support in
Class IIb, Level of Evidence: C
IABP insertion should be considered in patien
hemodynamic instability/cardiogenic shoc
mechanical complications.
Class IIa, Level of Evidence: C
Routine use of IABP in patients with cardioge
not recommended.
Class III, Level of Evidence: A
STEMI, 2012 (45) IABP may be considered for the treatment of
shock (Killip class IV) after STEMI.
Class IIb, Level of Evidence: B
UA/NSTEMI, 2011 (51) No recommendations.
The Impella device is manufactured by Abiomed Inc. (Danvers, Massachusetts). The Tan
ACS ¼ acute coronary syndrome; IABP ¼ intra-aortic balloon pump; NSTEMI ¼ non–ST-
myocardial infarction; UA ¼ unstable angina.patients who had crossed over. No systematic differ-
ences were found between groups at baseline or
regarding the extent of revascularization; both are
potential confounders (35,36). The etiology of death,
however, is unknown, hampering any efforts to
mechanistically understand the reduced mortality
seen in the elective IABP arm and limiting the ability
to make any robust cause-and-effect associations.
Since the trial was not originally designed to inves-
tigate all-cause mortality, inferences made can only
be hypothesis generating. Nevertheless, the results
should stimulate future studies to be powered
adequately for all-cause mortality and to incorporate
long-term surveillance so that differences not imme-
diately apparent may be detected later.
THE CRISP-AMI TRIAL. The CRISP AMI (Counter-
pulsation to Reduce Infarct Size Pre-PCI Acute
Myocardial Infarction) trial was a prospective, open,neous Circulatory Assist Devices During High-Risk PCI
Impella TandemHeart Extracorporeal Membrane Oxygenation
ion/Society for Cardiovascular Angiography and Interventions Recommendations
ded for patients with cardiogenic shock after STEMI who do not quickly stabilize
amic support device as an adjunct to PCI may be reasonable in carefully selected high-risk patients.
duit PCI.  PCI of a vessel subtending a large territory on a background of severely
depressed left ventricular function.
shock after STEMI
cological therapy.
Alternative left ventricular assist devices for circulatory support may be
considered in patients with refractory cardiogenic shock.
Class IIb, Level of Evidence: C
r continuing or
ite intensive
pre- or post-
tions of MI
No individual device recommendations.
iety of Cardiology Recommendations
ACS patients with cardiogenic shock may be considered.
ts with
k due to
nic shock is
No other individual device recommendations.
cardiogenic Left ventricular assist devices may
be considered for circulatory support for
patients in refractory shock post-STEMI on an
individual basis, taking into account the
experience of the group along with patient
age and comorbidities. They are not
recommended as ﬁrst-line treatment.
Class IIb, Level of Evidence: C
demHeart device is manufactured by CardiacAssist, Inc. (Pittsburgh, Pennsylvania).
segment elevation myocardial infarction; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation
TABLE 3 Meta-Analyses of Percutaneous Circulatory Assist Devices in Acute Myocardial Infarction With or Without Cardiogenic Shock
First Author (Ref.#),
Year Published
No. of Studies
Identiﬁed n
Device(s) Under
Investigation Clinical Scenario Primary Endpoint Secondary Endpoint Salient Messages
Sjauw et al.
(74), 2009
7 RCTs in ﬁrst M-A,
9 cohort studies
in second M-A
1,009
10,529
IABP STEMI and STEMI
complicated by CS
All-cause mortality at
30 days
LVEF, stroke, bleeding First M-A
IABP in STEMI was not associated with a change in
30-day mortality (p ¼ 0.75).
IABP was associated with a signiﬁcant increase in the
rate of stroke (p ¼ 0.03) and bleeding (p ¼ 0.02).
Second M-A
In the thrombolysis era, IABP associated with 18%
lower 30-day mortality (p < 0.0001).
In PPCI studies, IABP associated with 6% higher
30-day mortality (p ¼ 0.0008).
Cheng et al.
(79), 2009
2 RCTs, IABP vs.
TandemHeart
1 RCT, IABP vs.
Impella
100 IABP (n ¼ 47) vs.
Impella or
TandemHeart
(n ¼ 53)
Cardiogenic shock 30-day mortality Cardiac index, MAP,
PCWP, leg ischemia,
major bleeding
No signiﬁcant difference in survival at 30 days
(p ¼ 0.80).
Percutaneous LVAD gave rise to a higher cardiac index
(p < 0.01), higher MAP (p < 0.01), and lower
PCWP (p < 0.05).
Similar rates of leg ischemia were observed in both
groups (p ¼ 0.13).
Bleeding was more frequently associated with the
TandemHeart device (p < 0.01).
Hemolysis was signiﬁcantly higher with the Impella
device (p < 0.05).
Bahekar et al.
(75), 2012
16; 13 prospective,
3 retrospective
Note: Majority of
patients came
from NRMI-2
Registry (4)
(n ¼ 23,180)
27,690 IABP IABP vs. no IABP use
in AMI with or
without CS
In-hospital mortality,
reinfarction, recurrent
ischemia
Moderate and severe
bleeding at 7 days
No difference in in-hospital mortality with or without
IABP in AMI without CS (RR: 1.11,
95% CI: 0.69–1.78, p ¼ 0.67).
IABP was associated with signiﬁcantly improved
in-hospital mortality when used in AMI with CS
(RR: 0.72, 95% CI: 0.60–0.86, p < 0.0004).
No signiﬁcant reduction in reinfarction or recurrent
ischemia with IABP.
IABP was associated with a signiﬁcant increase in
the risk of moderate (p [ 0.04) and major
(p < 0.0001) bleeding.
Cassese et al.
(76), 2012
6, all RCTs 1,054 IABP (49.1% IABP
vs. 50.9%
no IABP)
AMI without CS All-cause death CHF, reinfarction,
recurrent myocardial
ischemia, CVA,
bleeding
IABP did not reduce the risk of all-cause death (4.4%
vs. 4.1%, OR: 1.11, 95% CI: 0.49–2.54, p ¼ 0.80).
IABP did not reduce the risk of CHF (17.1% vs. 18.0%,
OR: 0.92, 95% CI: 0.43–1.96, p ¼ 0.83).
IABP did not reduce the risk of reinfarction (5.3% vs.
7.7%, OR: 0.68, 95% CI: 0.23–1.76, p ¼ 0.42).
IABP caused signiﬁcantly more bleeding (21.4% vs.
16.1%, OR: 1.46, 95% CI: 1.05–2.04, p [ 0.02).
Chen et al.
(77), 2013
10, all RCTs 2,037 IABP High-risk reperfusion
therapy, CS excluded
from this M-A
30-day mortality,
$6-month mortality
Composite incidence of
reischemia and HF
No signiﬁcant difference between IABP and no IABP
with regard to early mortality (OR: 0.79, 95%
CI: 0.48–1.29, p ¼ 0.34).
IABP signiﬁcantly reduced long-term mortality
(OR: 0.63, 95% CI: 0.45–0.90, p [ 0.01).
Subgroup analysis of more contemporary studies
(n [ 5) all using PCI still conﬁrmed a signiﬁcant
risk reduction in 6-month mortality (p [ 0.01)
and ‡6-month mortality (p [ 0.002) with
IABP use.
IABP associated with 25% relative risk reduction of
reischemia and HF events (p ¼ 0.04).
IABP signiﬁcantly reduced the risk of 30-day
reischemia rate (p ¼ 0.01).
Continued on the next page
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237multicenter RCT undertaken to determine whether
prophylactic IABP insertion within 6 h of pain onset
and planned primary PCI (PPCI) for anterior STEMI
(without CS) could reduce the mean infarct size, as
measured by cardiac magnetic resonance imaging
between 3 and 5 days post-intervention (37). IABP
insertion in the PPCI alone group was at the opera-
tor’s discretion for indications such as persistent
hypotension, overt CS, malignant arrhythmias, and
AMI complications. Of note, 15 patients (8.5%)
initially receiving standard care crossed over to
IABP. This again highlights the susceptibility of
these high-risk patients to hemodynamic collapse,
which in turn further supports the argument for
standby MCS.
The primary efﬁcacy endpoint was not signiﬁcantly
different between the 2 groups. Secondary cardiac
magnetic resonance imaging measures such as mean
LV ejection fraction and LV systolic volume were also
similar. There were no signiﬁcant differences in major
bleeding/transfusion or major vascular complications
at 30 days. By 6 months, mortality rates along with
the composite endpoint of death, recurrent MI, or
new or worsening heart failure had not diverged.
There was a signiﬁcant difference in the exploratory
composite endpoint of time to death, shock, or new or
worsening heart failure in favor of PPCI plus IABP
(5.0% vs. 12.0%, p ¼ 0.03). Like BCIS-1, longer term
follow-up is planned for the CRISP-AMI population,
which may uncover further trends as events accrue.
For now, the investigators postulate that mean
ischemic times (time between symptom onset to ﬁrst
device application) of longer than 3 h may have
been outside a therapeutic window in which sig-
niﬁcant myocardial salvage could have occurred
(37–39). This explanation contradicts an RCT in
which LV infarct size was signiﬁcantly reduced by
mechanical reperfusion in AMI patients presenting
12 to 48 h after symptom onset (40). Overall, the
trial was underpowered for the evaluation of clinical
outcomes after IABP implantation. Moreover, the
cohort studied was not that sick. Couple that with
early reperfusion from PPCI having such a dominant
effect on myocardial salvage and hence mortality, it
could be argued that any further adjunctive mea-
sures would add very little to the net clinical
beneﬁt. A strategy of routine prophylactic IABP im-
plantation in PPCI of STEMI without CS cannot
therefore be advocated.
THE IABP-SHOCK II (INTRAAORTIC BALLOON PUMP
IN CARDIOGENIC SHOCK II) TRIAL. The trial enrolled
600 patients with CS complicating AMI proceeding to
early revascularization (almost double that of the
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238landmark SHOCK trial), who were then randomized in
an open-label manner to IABP or no IABP (3,41).
Importantly, the timing of MCS was at the discretion
of the operator and could be applied before PCI (n ¼
37, 13.4%) or immediately post-procedure (n ¼ 240,
86.6%). The trial did not achieve its primary endpoint
of 30-day all-cause mortality (IABP group 39.7% vs.
control group 41.3%; p ¼ 0.69). Indeed, the mortality
rate itself appears relatively low compared with the
original SHOCK trial (30-day mortality rate of 46.7%
in the early revascularization arm), although trends
in hospital outcomes associated with CS do conﬁrm
declining short-term death rates over time (42.0%
case fatality rate in 2005) (3,42). As such IABP-
SHOCK II may well have been underpowered to
detect a difference in mortality. The “low” mortality
rate also calls into question the deﬁnition of CS
used by the investigators. There was an absence
of mixed venous saturation, wedge pressure, and
CI parameters used to satisfy a CS diagnosis (3,4).
Moreover, there were a signiﬁcant proportion of
patients (IABP group 42.2% vs. control group 47.8%)
who required resuscitation before randomization.
Given that resuscitation for more than 30 min was
an exclusion criteria, we can only assume that these
patients required resuscitation for 30 min or longer,
during which time their hemodynamic indices
may have transiently satisﬁed a protocol-driven CS
diagnosis. Furthermore, w80% of patients in each
arm also required mechanical ventilation for a me-
dian of 3 days and spent a median of 6 days in the
intensive care unit. The lower-than-expected mor-
tality could thus be attributed to superior critical
care management. Although entirely speculative,
it does reinforce the notion that the population
under investigation was not entirely representative
of true CS.
There was also no signiﬁcant difference in mor-
tality between either MCS strategy (pre-PCI 36.4% vs.
post-PCI 36.8%; p ¼ 0.96). That patients received
an IABP post-procedure would suggest that their
perceived hemodynamic instability at randomization
was not severe enough to warrant prophylactic sup-
port. On the contrary, had there been a protocol
stipulation for prophylactic counterpulsation only,
we might have observed greater beneﬁt because
susceptibility to circulatory collapse is heightened
during PCI in this cohort. There was also a liberal use
of catecholamines in almost 90% of patients in both
arms at randomization. Given that a standout
advantage of using MCS is to obviate the need to
continue pharmacological circulatory support, it
would seem to defeat the purpose of investigating
IABP effects if these agents were so widely used.Catecholamines were continued for a median of 3
days in each trial arm. At 1 year, mortality remained
similar in both arms (IABP group 52% vs. control
group 51%; p ¼ 0.91). IABP insertion did no excess
harm, with no signiﬁcant differences between either
group in terms of stroke, bleeding, sepsis, or periph-
eral ischemic complications requiring intervention
(41).
Are we expecting too much from a device
that can only augment systemic blood ﬂow by
<500ml/min/m2? Bear inmind the pathophysiology of
CS is not only a compromise in cardiac contractile
function but also encompasses a multiorgan dysfunc-
tion syndrome secondary to peripheral hypoperfusion
along with microcirculatory dysfunction, often
complicated by a systemic inﬂammatory response
syndrome and sepsis (11,43). In light of these equivocal
results, the use of IABP in CS complicating AMI
has been downgraded from a previous Class I indica-
tion to a Class IIa and Class IIb recommendation in the
most recent U.S. and European STEMI guidelines,
respectively (Table 2) (44,45).
IMPELLA
The Impella (Abiomed Inc., Danvers, Massachsetts)
is positioned across the aortic valve under radio-
graphic or echocardiographic guidance. It aspirates
blood from the left ventricle into the ascending
aorta. Impella-mediated LV unloading reduces end-
diastolic wall stress, improves diastolic compliance,
increases aortic and intracoronary pressure and cor-
onary ﬂow velocity reserve, and stimulates a decrease
in coronary microvascular resistance (46,47). This
may allow for recovery of hibernating or stunned
myocardium. The pigtail conformation promotes
stable positioning in the left ventricle and prevents
adherence to the endocardium. The mode of
deployment underscores the importance of ruling
out pre-existing aortic valve disease or LV mural
thrombus before implantation.
The Impella 5.0 requires surgical cutdown of the
femoral or axillary artery and so is not truly percu-
taneous. The Impella 2.5 received U.S. Food and Drug
Administration approval in June 2008 and can pro-
vide antegrade ﬂow up to 2.5 l/min (Figure 1). The
newly introduced Impella CP (known as cVAD in
Europe) received U.S. Food and Drug Administration
approval in September 2012 and is based on the same
2.5 platform but can provide ﬂow up to 4.0 l/min.
The IMPRESS in Severe Shock (IMPella versus IABP
REduces mortality in STEMI patients treated with
primary PCI IN SEVERE and deep cardiogenic SHOCK)
trial (NTR3450) will compare the Impella cVAD with
FIGURE 3 Case Vignette #1
Intra-aortic balloon counterpulsation facilitated emergency angioplasty for acute unpro-
tected left main stem coronary artery occlusion. See Online Appendix for detailed
commentary of this case vignette.
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239IABP in patients with CS complicating AMI awaiting
PPCI. Current guideline recommendations for the
Impella are shown in Table 2 (44,45,48–51).
The use of the Impella in high-risk PCI including
CS is feasible according to registries and small single-
center studies, with demonstrable improvements
in CI and myocardial performance (Online Appendix).
However, the increase in vascular access–related
issues and the propensity for hemolysis due to the
high rotational speed of the axial ﬂow pump do
not appear to be outweighed by any signiﬁcant gains
in survival. The EUROSHOCK registry reported a
30-day mortality of 64.2% in patients presenting
with CS complicating AMI, a ﬁgure compounded by
access site complications occurring in 24.2% of the
study cohort (52). Potentially, the excess mortality
here could have been secondary to a selection bias
isolating the very sickest patients with a poor
hemodynamic proﬁle and imminent risk of death.
Indeed, Impella support was only instituted once CS
had become refractory to high-dose inotropes and
IABP (52).
The ISAR-SHOCK (Efﬁcacy Study of LV Assist
Device to Treat Patients With Cardiogenic Shock)
study randomized 25 patients with AMI complicated
by CS to IABP (n ¼ 13) or the Impella LP 2.5 (n ¼ 12)
implanted post-revascularization (53). The Impella
achieved signiﬁcantly greater augmentation of CI, but
this did not result in improved 30-day mortality.
There were nonsigniﬁcant trends toward greater
requirements for packed red blood cells and fresh
frozen plasma for the Impella group, further empha-
sizing the issues associated with higher-proﬁle
devices.
The PROTECT II (Prospective Randomized Clinical
Trial of Hemodynamic Support with Impella 2.5
versus Intra-Aortic Balloon Pump in Paitents Under-
going High-Risk Percutaneous Coronary Intervention)
study is the largest randomized comparison of the
Impella and IABP to support nonemergent high-risk
PCI to date (54). It did not meet its target recruit-
ment of 654 patients because the trial was terminated
early for reasons of futility. The primary composite
endpoint of major adverse events at hospital
discharge or 30 days (whichever came sooner) in the
intention-to-treat population (n ¼ 448) was similar in
both arms (Impella 35.1% vs. IABP 40.1%; p ¼ 0.277).
At 90 days, there was a nonsigniﬁcant trend toward
a lower major adverse event rate for the Impella (p ¼
0.066). At 90 days in the per-protocol population
(n ¼ 427), that trend became signiﬁcant (p ¼ 0.023),
suggesting that the Impella may hold promise over
the longer term. The patient cohort studied in PRO-
TECT II was similar to that of BCIS-1 (34). Given thatthe BCIS-1 study did not support the use of elective
IABP insertion before high-risk PCI, it would seem
intuitive to expect that the superior hemodynamic
support provided by the Impella would offer no
supplementary impact on adverse outcomes.
TANDEMHEART
The TandemHeart (CardiacAssist, Inc., Pittsburgh,
Pennsylvania) is inserted via the femoral vein and
right atrium into the left atrium via a transseptal
puncture. The outﬂow cannula is inserted in either
femoral artery and positioned at the level of the
aortic bifurcation, providing left heart bypass at a
FIGURE 4 Case Vignette #2
The Impella 2.5 (Abiomed Inc., Danvers, Massachsetts: red arrow) to provide essential
hemodynamic support during high-risk multivessel percutaneous coronary intervention.
See Online Appendix for detailed commentary of this case vignette.
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240ﬂow rate of w4 l/min into the lower abdominal aorta
or iliac arteries (Figure 1). Studies of the TandemHeart
in severe refractory CS have shown the device to
improve CI, MAP, and reduce pulmonary capillary
wedge pressure, pulmonary artery pressure, and
central venous pressure, leading to decreased ﬁlling
pressures in both ventricles (55–58). This culminates
in an amelioration of myocardial workload and oxy-
gen demand.
The TandemHeart is a high-proﬁle system; thus,
critical limb ischemia, bleeding, and vascularcomplications are a major concern. This was borne
out in a randomized comparison of IABP (n ¼ 20) with
the TandemHeart (n ¼ 21) in patients revascularized
for AMI complicated by CS (59). Although the device
improved hemodynamic and metabolic variables
more effectively, this did not result in a survival
advantage. Furthermore, severe bleeding and limb
ischemia occurred more frequently with the Tan-
demHeart. Single-center series have demonstrated
the device to be hemodynamically effective and
straightforward to deploy in expert hands (Online
Appendix). However, the arrival of the Impella CP,
which promises to maintain an equivalent ﬂow rate
based on a lower-proﬁle cannula system, may impede
the widespread dissemination of the TandemHeart in
the high-risk PCI arena.
EXTRACORPOREAL MEMBRANE
OXYGENATION
Venoarterial extracorporeal membrane oxygenation
(ECMO) is effectively a modiﬁed cardiopulmonary
bypass circuit that provides a continuous, non-
pulsatile CO that can be applied percutaneously via
cannulation of the femoral artery and vein (Figure 2)
(60,61). ECMO removes carbon dioxide from and adds
oxygen to venous blood via an artiﬁcial membrane,
thereby bypassing the pulmonary circulation (62). As
such, it is the only PCAD that also oxygenates the
blood. ECMO can provide signiﬁcant hemodynamic
support but has a propensity to increase LV afterload
and wall stress, which in turn can increase myocardial
oxygen demand and therefore limit any cardio-
protective beneﬁt.
The implantation procedure requires considerable
technical skill and full collaboration between the
cardiologist, surgeon, catheterization laboratory
staff, anesthesiologist, and perfusionist. The system
is composed of a venous reservoir, external centrif-
ugal blood pump, membrane oxygenator, and a
rewarming heparin-coated circuit. The technology
has become smaller and more portable. Systemic
anticoagulation with heparin is required to achieve an
activated clotting time of 150 to 180 s (63). Contrain-
dications to ECMO include signiﬁcant aortic valve
incompetence, severe peripheral arterial disease,
bleeding diathesis, recent stroke or head trauma, and
uncontrolled sepsis (62).
A retrospective analysis of prophylactic versus
standby cardiopulmonary support revealed signiﬁ-
cantly greater procedural morbidity (e.g., femoral
access site complications) in the former (41% vs.
9.4%, p < 0.01) but higher procedural mortality in
the latter (4.8% vs. 18.8%, p < 0.05) (64). The
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241investigators suggested that standby CPS was pref-
erable in the majority although patients with
LVEF <20% may beneﬁt from a prophylactic strategy.
Early institution of ECMO for STEMI complicated by
profound CS has been shown to signiﬁcantly reduce
30-day mortality when compared with an historical
cohort of patients not receiving cardiopulmonary
support (65). Monocentric observational studies and
individual case reports constitute the remainder of
the evidence base on ECMO-assisted high-risk PCI
(60,61,66–73). All conﬁrm the feasibility and efﬁcacy
of ECMO, but vascular complications remain a notable
problem. A reduction in platelet count, hemolysis,
and a consumptive coagulopathy along with systemic
heparinization can further increase the hemorrhagic
risk. Intrathoracic, abdominal, or retroperitoneal
hemorrhage not related to the access site may also
occur as a result. Since no RCT or meta-analysis data
are available for ECMO, current guidelines can only
be based on expert consensus (Table 2).
CAN META-ANALYSES
SHED LIGHT ON THE MATTER?
The majority of meta-analyses have studied outcomes
for IABP versus control in high-risk PCI (74–78). All
echo what we already know. In the PPCI era, IABP
does not confer a 30-day survival advantage when
used for AMI without CS (74–78). At 6 months or
longer, however, there appears to be a mortality
beneﬁt signal with an associated reduction in re-
ischemia and heart failure events (77). When the
analysis was limited to those with STEMI complicated
by CS, a signiﬁcantly improved in-hospital outcome
was noted in favor of IABP support, although much of
this beneﬁt emanated from the thrombolysis era
(74,75). This must be taken with a note of caution
because thrombolysed patients in those studies ten-
ded to be younger and male, and were more likely to
undergo subsequent revascularization (74). A single
meta-analysis compared the Impella and Tandem-
Heart with IABP (79). Ventricular assist devices
delivered superior hemodynamic support, although
use of all 3 resulted in similar 30-day mortality rates.
There were also similar rates of limb ischemia, but
bleeding occurred more often with the TandemHeart
and hemolysis with the Impella. The conclusions here
remain tenuous because the analysis was based on
just 100 patients (80) (Table 3).
DISCUSSION
Despite a sound physiological platform, the modest
uptake of PCADs to support high-risk PCI (22,23)reﬂects the equivocal results and mixed messages
emanating from the current evidence base and
latent uncertainty as to what constitutes high risk
outside of CS. From a clinical standpoint, the IABP,
Impella, TandemHeart, and ECMO should have a
place in high-risk PCI, although they cannot be
advocated as standard of care for every procedure.
It is up to the heart team to assess, on a case-
by-case basis, which patient may beneﬁt from a
particular device and thereafter ensure MCS avail-
ability as a standby adjunct in the catheterization
laboratory. This can only come from shared exper-
tise, familiarity with and conﬁdence in using all
4 adjuncts, supported by an experienced multi-
disciplinary team (Figures 3 and 4, Case Vignettes
#1 and #2). The onus should also be on device
companies to foster educational relationships with
centers undertaking high-risk PCI and to encourage
proctoring of operators keen to learn and gain
proﬁciency.
Moving forward, we must level the playing ﬁeld.
Akin to the consensus deﬁnitions proposed for stent
thrombosis, bleeding, and trials of transcatheter
aortic valve implantation (81–83), there must be a
willingness to establish standardized criteria to
deﬁne what high-risk PCI is. Thus far, only the
American College of Cardiology Foundation/Amer-
ican Heart Association/Society for Cardiovascular
Angiography and Interventions guideline writing
committee has documented these features (Table 2)
(48). It is a fundamental ﬁrst step in benchmarking
a degree of uniformity between future trials of
high-risk PCI to allow researchers, policymakers,
and clinicians alike to compare outcomes of a spe-
ciﬁc intervention with a degree of scientiﬁc and
statistical equipoise. Only then can we be more
proscriptive as to which combination of lesion
complexity and LV ejection fraction, for instance,
would indicate the use of a particular PCAD. The
same applies for trials of CS. The deﬁnition from
the outset should incorporate right heart catheteri-
zation parameters and mixed venous saturations to
ensure that the population under study truly re-
ﬂects a CS sample, although we do accept the im-
practicalities of conducting the former in critically
ill patients (3,4).
In the end, we return full circle to the days of
Harken, Kantrowitz, and Moulupoulos and the
essential features for a viable PCAD. We believe that
the IABP, Impella, TandemHeart, and ECMO fulﬁll
each criterion to some degree. It should no longer
be a case of determining which device is superior.
There should be a shift in emphasis moving forward
to identify the patient, anatomic, hemodynamic,
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242and procedural characteristics that signal adjunctive
MCS may be necessary, to prepare the subject and
catheterization laboratory accordingly, and then
to perform the PCI with the knowledge that a step-
wise increment in hemodynamic support can be
facilitated.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Deepak L. Bhatt, Brigham and Women’s Hospital
Heart & Vascular Center, 75 Francis Street, Boston,
Massachusetts 02115. E-mail: dlbhattmd@post.
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